Ligand Pharmaceuticals Incorporated (LGND)

NGM – Real vaqt narxi. Valyuta: USD

220.72

-1.28 (-0.58%)

Bozor ochiq: May 13, 2026, 10:00 AM EDT

09.05.2026

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

08.05.2026

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

07.05.2026

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

05.05.2026

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.

28.04.2026

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.

27.04.2026

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold.

27.04.2026

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Ligand Reports First Quarter 2026 Financial Results

28.04.2026

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

27.04.2026

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

27.04.2026

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50 1 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027 2 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla.

Ligand Pharmaceuticals Incorporated (LGND)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Reports First Quarter 2026 Financial Results

Ligand to Participate in May Investor Conferences

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Videolar

No Data

Press-relizlar

Ligand Reports First Quarter 2026 Financial Results

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Reports First Quarter 2026 Financial Results

Ligand to Participate in May Investor Conferences

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Videolar

No Data

Press-relizlar

Ligand Reports First Quarter 2026 Financial Results

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Search stocks

Ligand Pharmaceuticals Incorporated (LGND)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Reports First Quarter 2026 Financial Results

Ligand to Participate in May Investor Conferences

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Videolar

No Data

Press-relizlar

Ligand Reports First Quarter 2026 Financial Results

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Reports First Quarter 2026 Financial Results

Ligand to Participate in May Investor Conferences

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Videolar

No Data

Press-relizlar

Ligand Reports First Quarter 2026 Financial Results

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator